Radioactive 'Smart Bomb' targets Hard-to-Treat prostate cancer

NCT ID NCT03042468

Ongoing Disease control Sponsor: Weill Medical College of Cornell University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests a radioactive drug called 177Lu-PSMA-617 in men with advanced prostate cancer that has stopped responding to hormone therapy. The drug seeks out and delivers radiation directly to cancer cells. The trial aims to find the safest effective dose and see if it can lower PSA levels. About 50 men are participating in this early-phase study.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 177Lu-PSMA-617 (a radioactive drug that targets prostate cancer cells)
What this could lead to: If it works, this could provide a new, targeted treatment option for men with advanced prostate cancer that has stopped responding to hormone therapy.
What could go wrong: This is an early-phase trial with only 50 participants, so results may not apply to everyone. The drug is radioactive and may cause side effects like dry mouth, fatigue, or low blood counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Tulane Cancer Center Clinic

New Orleans, Louisiana, 70112, United States
Weill Cornell Medical College

New York, New York, 10021, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.